-
Atomoxetine,
formerly sold
under the
brand name Strattera, is a
selective norepinephrine reuptake inhibitor (sNRI)
medication used to
treat attention...
- (Edronax),
developed as a first-line
therapy for
major depressive disorder.
Atomoxetine (Strattera) is
another potent and
selective NRI
which is also effective...
- effect. For ADHD, the
effectiveness of
methylphenidate is
comparable to
atomoxetine but
modestly lower than amphetamines,
alleviating the
executive functioning...
- non-stimulant medications,
atomoxetine and viloxazine, are
approved by the FDA and in
other countries for the
treatment of ADHD.
Atomoxetine, due to its lack of...
- an extended-release form,
latterly with
comparable effectiveness to
atomoxetine and methylphenidate. Side
effects of
viloxazine include insomnia, headache...
-
studies on
medical treatments are limited, however,
research suggests that
atomoxetine and
lisdexamfetamine may be used to
treat CDS. The
condition was previously...
- naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole,
atomoxetine, dextroamphetamine, and modafinil. A 2018
systematic review and network...
- the following:
Selective norepinephrine reuptake inhibitors Marketed Atomoxetine (Strattera)
Reboxetine (Edronax, Vestra)
Viloxazine (Qelbree, Vivalan)...
- in Canada. The non-stimulant
atomoxetine (Strattera) may be an
effective treatment for
adult ADHD.
Although atomoxetine has a half-life
similar to stimulants...
- for
treating Parkinson's disease, influenza, and Alzheimer's disease.
Atomoxetine: a
norepinephrine reuptake inhibitor used in the
treatment of ADHD. AZD6765...
